Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide - Wikidata - wikimedia - TriplyDB

Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide

Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide

http://www.wikidata.org/entity/Q42135667

about

Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats.Do ASARM peptides play a role in nephrogenic systemic fibrosis?The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies.The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation.Understanding nephrogenic systemic fibrosis Analytical interference in serum iron determination reveals iron versus gadolinium transmetallation with linear gadolinium-based contrast agents.Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.Sheffield 2nd International Workshop on experimental studies of nephrogenic systemic fibrosis, 15th June 2012, Sheffield, UK.

P2860

Q30410917-3388BC63-D0E9-44DF-9C24-F4C1BF090659 Q36027601-D57C12DB-6529-4F2F-A5A7-41A080DF6342 Q36237106-6D3A50FF-9461-49F2-8159-925F32E91241 Q38254508-0DD2BEF4-A916-4ECB-8B64-B2D936BEA570 Q38516664-7F3A8A9B-BC6C-4CC7-9365-0E939FD0F9D6 Q41082208-42537AC9-4168-406B-B769-A3132B8B7F9C Q41545279-232D7D51-13C8-4DB0-A51B-1FB235410365 Q42981019-9C4DF036-6503-43FB-A6B1-84F87DCCF359 Q46628940-110842D0-10BB-4B13-8881-AB677400EE40 Q47867533-45350B66-536C-4E98-B3C7-20B1385C2C0B Q55511523-0CD8D845-0A36-4842-B597-79142375AFA8

P2860

Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide

http://www.wikidata.org/entity/Q42135667

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Hyperphosphataemia sensitizes ...... ibrotic effects of gadodiamide

@en

Hyperphosphataemia sensitizes ...... ibrotic effects of gadodiamide

@nl

type

label

Hyperphosphataemia sensitizes ...... ibrotic effects of gadodiamide

@en

Hyperphosphataemia sensitizes ...... ibrotic effects of gadodiamide

@nl

prefLabel

Hyperphosphataemia sensitizes ...... ibrotic effects of gadodiamide

@en

Hyperphosphataemia sensitizes ...... ibrotic effects of gadodiamide

@nl

P1433

Q42135667-71D13B27-892B-47E9-8D0E-1375F5F4D84C

P1476

Q42135667-5BE52551-7DF4-41B9-B360-439E6BDD0FCE

P2093

Q42135667-0757535F-DA4C-461F-830D-F9126DAE8EA2

Q42135667-0D202F88-5A60-4DD0-92F2-B3C6BCE18F2C

Q42135667-188DDA42-2A78-4A8F-960A-05F432C4BAF0

Q42135667-2E6ACF10-3081-4C6D-A9B3-E49E571DDBC5

Q42135667-4AD9DC78-54D6-4D31-A52C-D2395EBCEF02

Q42135667-5CD4FE18-C071-4F33-8D39-99E7F5C85F79

Q42135667-87501842-FCE8-4096-9BDB-2879AF7C74ED

Q42135667-93A7F619-BDCE-4A32-B2DD-3B0DB336C247

Q42135667-A93C3CE8-5138-4D85-ADA1-E154666DAC09

Q42135667-B84EA8E0-4736-420F-AC89-BFFC107FAF3B

P2860

Q42135667-02317A9F-B911-4705-A3A3-98164EF0F676

Q42135667-07CF1889-BA04-4E89-A7A5-319127587843

Q42135667-08ED0C86-B577-461E-9C61-97944E69EFD7

Q42135667-16169709-5964-4963-9A8E-736060703C89

Q42135667-28E769F1-46C0-4EC6-A3CC-4441320198CC

Q42135667-2959CD1F-0C4D-41C4-87EC-57B01F1BDB1E

Q42135667-2CD76B44-5E5A-4DF8-BCC8-58D847E838DA

Q42135667-3372593A-CBEA-4255-9F79-435A7C17433E

Q42135667-37A5BAEA-5EC7-4D28-874E-CB922514158B

Q42135667-4218BBF9-68E7-4E52-837B-CB2C73493B08

P304

Q42135667-4B977C9A-1518-4743-A14A-012D853F0C05

P31

Q42135667-128BE15A-2DE2-46FF-AA3B-5F1B06A66602

P356

Q42135667-634F2172-BB1E-4D42-9822-EB0C1566FECE

P407

Q42135667-6DAF3496-44B1-4CC5-81FB-13651414EA8F

P433

Q42135667-9DE3316D-9067-41D6-8104-CC6C270D7CB9

P478

Q42135667-856C148C-8EA5-4599-AE38-66E5F384E015

P577

Q42135667-4F4527F2-CB6E-48FE-86F0-1D2FB6461C39

P5875

Q42135667-7A04D1B5-A626-4284-9707-8432B770F471

P698

Q42135667-01305459-151D-473C-827C-F4ABAA445FE1

P932

Q42135667-581DB27C-09B0-4793-A153-DAB203523240

P356

J.1476-5381.2011.01585.X

P1433

British Journal of Pharmacology

P1476

Hyperphosphataemia sensitizes ...... ibrotic effects of gadodiamide

@en

P2093

A Dencausse

http://www.w3.org/2001/XMLSchema#string

C Corot

http://www.w3.org/2001/XMLSchema#string

C Factor

http://www.w3.org/2001/XMLSchema#string

C Mandet

http://www.w3.org/2001/XMLSchema#string

F Daubiné

http://www.w3.org/2001/XMLSchema#string

F Massicot

http://www.w3.org/2001/XMLSchema#string

G Jestin

http://www.w3.org/2001/XMLSchema#string

Jm Idée

http://www.w3.org/2001/XMLSchema#string

M Port

http://www.w3.org/2001/XMLSchema#string

N Bouzian

http://www.w3.org/2001/XMLSchema#string

P2860

Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Prolyl 4-hydroxylase

Metalloproteinases and their inhibitors in matrix remodeling

Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.

Nephrogenic systemic fibrosis.

Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis.

Fibroblast response to gadolinium: role for platelet-derived growth factor receptor

Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects.

TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing.

Control of hyperphosphatemia among patients with ESRD.

P304

1151-1162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.2011.01585.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4b

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51478065

http://www.w3.org/2001/XMLSchema#string

P698

21740412

http://www.w3.org/2001/XMLSchema#string

P932

3346252

http://www.w3.org/2001/XMLSchema#string